Tscan Historical Balance Sheet

TCRX Stock

USD 4.77 0.13 2.80%

Trend analysis of Tscan Therapeutics balance sheet accounts such as Total Stockholder Equity of 77.3 M, Net Tangible Assets of 120.1 M, Property Plant And Equipment Net of 38.9 M or Current Deferred Revenue of 8.1 M provides information on Tscan Therapeutics' total assets, liabilities, and equity, which is the actual value of Tscan Therapeutics to its prevalent stockholders. By breaking down trends over time using Tscan Therapeutics balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Covid

Financial Statement Analysis is much more than just reviewing and examining Tscan Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Tscan Therapeutics is a good buy for the upcoming year.

Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Tscan Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For more information on how to buy Tscan Stock please use our How to Invest in Tscan Therapeutics guide.

About Tscan Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Tscan Therapeutics at a specified time, usually calculated after every quarter, six months, or one year. Tscan Therapeutics Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Tscan Therapeutics and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Tscan currently owns. An asset can also be divided into two categories, current and non-current.

Tscan Therapeutics Balance Sheet Chart

At this time, Tscan Therapeutics' Short and Long Term Debt Total is fairly stable compared to the past year. Net Tangible Assets is likely to rise to about 120.1 M in 2024, whereas Total Assets are likely to drop slightly above 166.9 M in 2024.

Total Assets Short Long Term Debt Total Other Current Liab Total Current Liabilities

Add Fundamental

Total Assets

Total assets refers to the total amount of Tscan Therapeutics assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Tscan Therapeutics books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Current Liabilities

Total Current Liabilities is an item on Tscan Therapeutics balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Tscan Therapeutics are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Most accounts from Tscan Therapeutics' balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Tscan Therapeutics current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Tscan Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For more information on how to buy Tscan Stock please use our How to Invest in Tscan Therapeutics guide.At this time, Tscan Therapeutics' Short and Long Term Debt Total is fairly stable compared to the past year. Net Tangible Assets is likely to rise to about 120.1 M in 2024, whereas Total Assets are likely to drop slightly above 166.9 M in 2024.

	2021	2022	2023	2024 (projected)
Short and Long Term Debt Total	6.0M	86.0M	92.4M	97.1M
Total Assets	188.1M	199.1M	272.1M	166.9M

Short Long Term Debt Total Total Assets

Tscan Therapeutics balance sheet Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Tangible Assets	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Non Current Liabilities Total	Capital Lease Obligations	Other Current Assets	Other Stockholder Equity	Total Liab	Net Invested Capital	Property Plant And Equipment Gross	Total Current Assets
Total Assets		0.84	0.94	0.91	0.96	0.92	0.91	0.71	-0.39	-0.92	0.69	0.94	0.92	1.0	0.99	0.98	-0.8	0.71	0.07	0.84	0.7	0.96	0.47	0.95	0.72	0.98
Short Long Term Debt Total	0.84		0.75	0.75	0.69	0.72	0.93	0.5	0.08	-0.96	0.73	0.68	0.93	0.8	0.79	0.75	-0.71	0.67	0.47	1.0	0.38	0.7	0.75	0.84	0.83	0.74
Other Current Liab	0.94	0.75		0.99	0.9	0.86	0.82	0.89	-0.42	-0.89	0.77	0.88	0.82	0.95	0.92	0.95	-0.89	0.75	0.04	0.76	0.69	0.94	0.48	0.89	0.76	0.95
Total Current Liabilities	0.91	0.75	0.99		0.85	0.82	0.81	0.93	-0.38	-0.88	0.86	0.85	0.82	0.91	0.89	0.9	-0.95	0.67	0.06	0.76	0.7	0.92	0.51	0.85	0.73	0.9
Total Stockholder Equity	0.96	0.69	0.9	0.85		0.98	0.78	0.7	-0.62	-0.82	0.57	0.99	0.79	0.98	0.97	0.99	-0.75	0.57	-0.2	0.69	0.83	0.98	0.21	0.95	0.6	0.99
Net Tangible Assets	0.92	0.72	0.86	0.82	0.98		0.74	0.7	-0.63	-0.84	0.59	0.99	0.76	0.95	0.93	0.95	-0.76	0.48	-0.25	0.72	0.87	0.97	0.16	0.98	0.63	0.95
Property Plant And Equipment Net	0.91	0.93	0.82	0.81	0.78	0.74		0.54	-0.01	-0.9	0.77	0.75	1.0	0.88	0.9	0.82	-0.75	0.68	0.43	0.93	0.44	0.78	0.74	0.81	0.67	0.81
Current Deferred Revenue	0.71	0.5	0.89	0.93	0.7	0.7	0.54		-0.51	-0.69	0.8	0.73	0.55	0.75	0.7	0.75	-0.93	0.49	-0.16	0.51	0.73	0.82	0.28	0.7	0.6	0.75
Net Debt	-0.39	0.08	-0.42	-0.38	-0.62	-0.63	-0.01	-0.51		0.14	-0.07	-0.66	-0.05	-0.47	-0.45	-0.53	0.35	0.06	0.89	0.08	-0.85	-0.62	0.59	-0.47	0.0	-0.54
Retained Earnings	-0.92	-0.96	-0.89	-0.88	-0.82	-0.84	-0.9	-0.69	0.14		-0.75	-0.8	-0.9	-0.9	-0.87	-0.88	0.81	-0.75	-0.28	-0.96	-0.54	-0.84	-0.64	-0.93	-0.9	-0.87
Accounts Payable	0.69	0.73	0.77	0.86	0.57	0.59	0.77	0.8	-0.07	-0.75		0.61	0.78	0.69	0.71	0.61	-0.95	0.39	0.28	0.74	0.54	0.68	0.63	0.64	0.54	0.61
Cash	0.94	0.68	0.88	0.85	0.99	0.99	0.75	0.73	-0.66	-0.8	0.61		0.77	0.97	0.96	0.97	-0.78	0.49	-0.26	0.68	0.89	0.99	0.16	0.95	0.57	0.97
Non Current Assets Total	0.92	0.93	0.82	0.82	0.79	0.76	1.0	0.55	-0.05	-0.9	0.78	0.77		0.89	0.91	0.83	-0.76	0.66	0.4	0.93	0.48	0.8	0.71	0.83	0.66	0.82
Non Currrent Assets Other	1.0	0.8	0.95	0.91	0.98	0.95	0.88	0.75	-0.47	-0.9	0.69	0.97	0.89		0.99	0.99	-0.82	0.66	-0.01	0.8	0.76	0.98	0.4	0.96	0.69	0.99
Other Assets	0.99	0.79	0.92	0.89	0.97	0.93	0.9	0.7	-0.45	-0.87	0.71	0.96	0.91	0.99		0.97	-0.81	0.61	0.01	0.79	0.75	0.96	0.41	0.93	0.61	0.97
Cash And Short Term Investments	0.98	0.75	0.95	0.9	0.99	0.95	0.82	0.75	-0.53	-0.88	0.61	0.97	0.83	0.99	0.97		-0.77	0.69	-0.09	0.75	0.76	0.98	0.33	0.96	0.7	1.0
Common Stock Total Equity	-0.8	-0.71	-0.89	-0.95	-0.75	-0.76	-0.75	-0.93	0.35	0.81	-0.95	-0.78	-0.76	-0.82	-0.81	-0.77		-0.45	-0.03	-0.71	-0.74	-0.85	-0.46	-0.78	-0.61	-0.78
Common Stock Shares Outstanding	0.71	0.67	0.75	0.67	0.57	0.48	0.68	0.49	0.06	-0.75	0.39	0.49	0.66	0.66	0.61	0.69	-0.45		0.44	0.68	0.09	0.57	0.69	0.6	0.83	0.69
Non Current Liabilities Total	0.07	0.47	0.04	0.06	-0.2	-0.25	0.43	-0.16	0.89	-0.28	0.28	-0.26	0.4	-0.01	0.01	-0.09	-0.03	0.44		0.47	-0.58	-0.19	0.89	-0.07	0.34	-0.1
Capital Lease Obligations	0.84	1.0	0.76	0.76	0.69	0.72	0.93	0.51	0.08	-0.96	0.74	0.68	0.93	0.8	0.79	0.75	-0.71	0.68	0.47		0.38	0.7	0.75	0.84	0.84	0.74
Other Current Assets	0.7	0.38	0.69	0.7	0.83	0.87	0.44	0.73	-0.85	-0.54	0.54	0.89	0.48	0.76	0.75	0.76	-0.74	0.09	-0.58	0.38		0.86	-0.18	0.77	0.28	0.76
Other Stockholder Equity	0.96	0.7	0.94	0.92	0.98	0.97	0.78	0.82	-0.62	-0.84	0.68	0.99	0.8	0.98	0.96	0.98	-0.85	0.57	-0.19	0.7	0.86		0.25	0.94	0.62	0.98
Total Liab	0.47	0.75	0.48	0.51	0.21	0.16	0.74	0.28	0.59	-0.64	0.63	0.16	0.71	0.4	0.41	0.33	-0.46	0.69	0.89	0.75	-0.18	0.25		0.33	0.62	0.32
Net Invested Capital	0.95	0.84	0.89	0.85	0.95	0.98	0.81	0.7	-0.47	-0.93	0.64	0.95	0.83	0.96	0.93	0.96	-0.78	0.6	-0.07	0.84	0.77	0.94	0.33		0.77	0.95
Property Plant And Equipment Gross	0.72	0.83	0.76	0.73	0.6	0.63	0.67	0.6	0.0	-0.9	0.54	0.57	0.66	0.69	0.61	0.7	-0.61	0.83	0.34	0.84	0.28	0.62	0.62	0.77		0.7
Total Current Assets	0.98	0.74	0.95	0.9	0.99	0.95	0.81	0.75	-0.54	-0.87	0.61	0.97	0.82	0.99	0.97	1.0	-0.78	0.69	-0.1	0.74	0.76	0.98	0.32	0.95	0.7

Click cells to compare fundamentals

Tscan Therapeutics Account Relationship Matchups

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

V	Visa Class A
GOOG	Alphabet Inc Class C
GOOG	Alphabet Inc Class C

Additional Tools for Tscan Stock Analysis

When running Tscan Therapeutics' price analysis, check to measure Tscan Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tscan Therapeutics is operating at the current time. Most of Tscan Therapeutics' value examination focuses on studying past and present price action to predict the probability of Tscan Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tscan Therapeutics' price. Additionally, you may evaluate how the addition of Tscan Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Tscan Historical Balance Sheet

About Tscan Balance Sheet Analysis

Tscan Therapeutics Balance Sheet Chart

Total Assets

Total Current Liabilities

Tscan Therapeutics balance sheet Correlations

Tscan Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Also Currently Popular

Additional Tools for Tscan Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Non Currrent Assets Other	+ 1.0	Total Assets
Capital Lease Obligations	+ 1.0	Short Long Term Debt Total
Non Current Assets Total	+ 1.0	Property Plant And Equipment Net
Total Current Assets	+ 1.0	Cash And Short Term Investments
Other Assets	+ 0.99	Total Assets
Total Current Liabilities	+ 0.99	Other Current Liab

Capital Lease Obligations	- 0.96	Retained Earnings
Retained Earnings	- 0.96	Short Long Term Debt Total
Common Stock Total Equity	- 0.95	Accounts Payable
Common Stock Total Equity	- 0.95	Total Current Liabilities
Net Invested Capital	- 0.93	Retained Earnings
Common Stock Total Equity	- 0.93	Current Deferred Revenue